Our customers can rest assured that we will continue to apply our corporate resources toward the goal of expanding the significant value and savings that BDI offers them, both today and in the future.
Columbia, SC (PRWEB) November 30, 2011
BDI Pharma, Inc. (BDI), the nation’s fastest growing national distributor of specialty biotherapeutics, announced that the company’s Oncology Sales in Q3 represented a thirty-two percent (32%) increase over Q2 2011. This continued expansion resulted in overall Sales Revenues for the third fiscal quarter (Q3) of 2011 reflecting an increase of more than thirty-six percent (36%) compared with the same time period in 2010.
In addition to growing its Oncology market share, BDI’s corporate initiatives associated with the promotion of its Protein Biotherapeutics product line - including Anti-Hemophilia Factor, Intravenous Immune Globulin, and Albumin (Human) – continued to demonstrate success trending significantly upward in a year-to-year comparison.
“Our success in establishing a foothold in Oncology is illustrative of the fact that the marketplace not only demands, but prefers, greater choice among Specialty Distributors,” stated a representative from BDI Pharma. “The progress we have achieved in the past three years, specifically in the Oncology subset of specialty distribution, validates the persistent, conservative expansion of our portfolio. We feel that the physician community has come to recognize that BDI consistently achieves what others often do not - bridging the gap between Oncology and Protein Therapies. Our customers can rest assured that we will continue to apply our corporate resources toward the goal of expanding the significant value and savings that BDI offers them, both today and in the future.”
About BDI Pharma, Inc.
Since 1995, BDI Pharma has defined its customer-centric approach to serving the nation's healthcare community through innovative supply solutions, unparalleled customer service, extensive product knowledge, 24/7 emergency availability and urgent-need delivery. An open-access resource for reference material, educational literature, market data and online ordering, bdipharma.com (ivig.com) has become an industry-renowned point of reference. Proprietary programs for specialty veterinarians -- 4legpharma.com; product consignment -- consignadvantage.com; flu pre-booking and general vaccine ordering -- securivax.com; and purchasing/reward programs -- qoreprogram.com and securigam.com round out a family of solutions tailored to the needs of the healthcare community at large.
BDI Pharma’s portfolio includes branded and generic specialty pharmaceuticals, chemotherapy products, vaccines, albumin, IVIG, coagulation factors, high-titer or “hyper” immune globulins, and other specialty injectables. BDI Pharma is recognized as an “ADR,” or Authorized Distributor of Record, for all of the manufacturers it represents.